Cocrystal Pharma, Inc.
19805 North Creek Parkway
Bothell, WA 98011
United States
877 262 7123
https://www.cocrystalpharma.com
版塊: Healthcare
行業: Biotechnology
全職員工: 12
高階主管
| 名稱 | 頭銜 | 支付 | 行使價 | 出生年份 |
|---|---|---|---|---|
| Dr. Roger D. Kornberg Ph.D. | Co-Founder, Chairman of the Board, Chief Scientist & Chairman of Scientific Advisory Board | 130k | 無 | 1947 |
| Dr. Sam Lee Ph.D. | Co-Founder, Co-CEO & President | 559.82k | 無 | 1960 |
| Mr. James J. Martin CPA, M.B.A. | Co-CEO, CFO & Corporate Secretary | 559.82k | 無 | 1967 |
描述
Cocrystal Pharma, Inc., a biotechnology company, focuses on the discovery and development of antiviral therapeutic treatments for serious and/or chronic viral diseases. It employs structure-based technologies to create antiviral drugs primarily to treat hepatitis C virus (HCV), influenza virus, coronavirus, norovirus, and respiratory virus infections. The company develops CC-31244, a HCV non-nucleoside polymerase inhibitor that has completed Phase II a clinical trial to treat HCV infection; and CC-42344, a PB2 inhibitor that has completed Phase I clinical trial for treating influenza infection. It is also involved in identifying and developing non-nucleoside polymerase inhibitors for norovirus infections. Cocrystal Pharma, Inc. has a license and research collaboration agreement with Merck Sharp & Dohme Corp. to discover and develop proprietary influenza A/B antiviral agents; and a license agreement with Kansas State University Research Foundation to develop antiviral compounds for the treatment of norovirus and coronavirus infections. The company is headquartered in Bothell, Washington.
公司管治
截至 無 止，Cocrystal Pharma, Inc. 的 ISS 管治質素評分為 無。 Pillar 分數正在審核中：無；董事會：無；股東權利：無；現金賠償：無。
